Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH)

Modern Pathology

Volumn 25, Issue 5, 2012, Pages 675-682

  Arnould, Laurent ^a   Roger, Pascal ^b   MacGrogan, Gaëtan ^c   Chenard, Marie Pierre ^d   Balaton, André ^e   Beauclair, Sophie ^f   Penault Llorca, Frederique ^g  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b NÎMES UNIVERSITY HOSPITAL   (France)

^c INSTITUT BERGONIÉ   (France)

^d HÔPITAL DE HAUTEPIERRE   (France)

^e Cabinet d'Anatomopathologie   (France)

^f Laboratoire Roche Pharma   (France)

^g CENTRE JEAN PERRIN   (France)

Author keywords

adjuvant; breast cancer; HER2; immunohistochemistry; in situ hybridization

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; CHROMOGENIC IN SITU HYBRIDIZATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FRANCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); NEEDLE BIOPSY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; SILVER IN SITU HYBRIDIZATION;

EID: 84860436625     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.201     Document Type: Article

References (33)

1. Simon R, Nocito A, Hubscher T, et al Patterns of her-2/neu amplification and overexpression in primary andmetastatic breast cancer. J Natl Cancer Inst 2001;93:1141-1146. (Pubitemid 32780965)
2. Wolff AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145. (Pubitemid 350003059)
3. Wolff AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43. (Pubitemid 46174133)
4. Ellis IO, Bartlett J, Dowsett M, et al. Best practice no 176. Updated recommendations for HER2 testing in the UK. J Clin Pathol 2004;57:233-237. (Pubitemid 38338829)
5. Penault-Llorca F, Vincent-Salomon A, Bellocq JP, et al. Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France. Ann Pathol 2010;30:357-373.
6. Hanna W, O'malley FP, Barnes P, et al. Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer. Curr Oncol 2007;14:149-153.
7. Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000;157:1467-1472.
8. Vincent-Salomon A, MacGrogan G, Couturier J, et al. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology 2003;42:337-347. (Pubitemid 36459811)
9. Vincent-Salomon A, MacGrogan G, Couturier J, et al. Groupe d'Etude des Facteurs Pronostiques par Immunohistochime dans les Cancers du Sein. Re: HER2 testing in the real world. J Natl Cancer Inst 2003; 95:628.
10. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002;94:855-857. (Pubitemid 34705058)
11. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing: National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-854. (Pubitemid 34705057)
12. Papouchado BG, Myles J, Lloyd RV, et al. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma. Comparison with FISH and assessment of interobserver reproducibility. Am J Surg Pathol 2010;34:767-766.
13. Dietel M, Ellis IO, Hö fler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch 2007;451:19-25.
14. Capizzi E, Gruppioni E, Grigioni AD, et al. Real time RT-PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: a comparative study with FISH, SISH, and Immunohistochemistry. Diagn Mol Pathol 2008;17:220-226.
15. Shousha S, Peston D, Amo-Takyi B, et al. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. Histopathology 2009;54:248-253.
16. Penault-Llorca F, Balaton A, Sabourin JC, et al. Immunochemistry evaluation of HER2 status in infiltration breast cancer: technical protocol and interpretation guidelines. Ann Pathol 2002;22:150-157. (Pubitemid 34453863)
17. Lowe AC, Roa N, Shintaku P, et al. Are FISH HER-2/neu results the same on core needle biopsy and excision in patients with breast cancer [abstract]. Mod Pathol 2010;23:55A.
18. Tsuda H, Kurosumi M, Umemura S, et al. HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens. BMC Cancer 2010;10:534.
19. D'Alfonso T, Liu YF, Monni S, et al. Accurately assessing HER-2/neu status in needle core biopsies in breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed. Am J Surg Pathol 2010;34:575-581.
20. Apple SK, Lowe AG, Rao PN, et al. Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer. Mod Pathol 2009;22:1151-1159.
21. Park SY, Kim KS, Lee TG, et al. The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer. Am J Surg 2009;1997:266-269.
22. Cahill RA, Walsh D, Landers RJ, et al. Preoperative profiling of symptomatic breast cancer by diagnostic core biopsy. Ann Surg Oncol 2006;13:45-51. (Pubitemid 43117644)
23. Streibel JM, Bhargava R, Horbinski C, et al. The equivocally amplified HER2 FISH result on breast core biopsy. Anat Pathol 2008;129:383-390.
24. Chivukula M, Bhargava R, Brufsky A, et al. Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases. Mod Pathol 2008;21:363-368. (Pubitemid 351441033)
25. Usami S, Moriya T, Amari M, et al. Reliability of prognostic factors in breast carcinoma determined by core needle biopsies. Jpn J Clin Oncol 2007;27: 250-255. (Pubitemid 47090677)
26. Burge CN, Chang HR, Apple SK. Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens? Breast 2006;15:167-172. (Pubitemid 44268916)
27. Erggelet J, Robe R, Holzhausen HJ, et al. Correlation of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR) expression as predicted by core biopsy with the immunohistochemical results of surgical breast cancer specimens. Breast Care 2007;2:94-98. (Pubitemid 46652413)
28. Lebeau A, Turzynski A, Braun S, et al. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. J Clin Oncol 2010;28:3264-3270.
29. Arnedos M, Nerurkar A, Osin P, et al. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol 2009;20:1948-1952.
30. Tamaki K, Sasano H, Ishida T, et al. Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients. Cancer Sci 2010;101:2074-2079.
31. Taucher S, Rudas M, Mader RM, et al. Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer. Wien Klin Wochenschr 2004;116:26-31. (Pubitemid 38313560)
32. Bilous M. Breast core needle biopsy: issues and controversies. Mod Pathol 2010;23:536-545.
33. Wolf V, Grobe R, Erggelet J, et al. The reliability of HER2-status determination from core-needle-biopsies and surgical specimens: a comparison of two established test methods (IHC, CISH) [abstract]. J Clin Oncol 2009;27:15S.